Bergmark et al. [112] revealed in the FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial that PCSK9 inhibition with evolocumab could decrease calcific aortic valve stenosis incidence in patients with cardiovascular disease. This evidence concerns the gene PCSK9 and cardiovascular disorder.